Targeted Pediatric High-Grade Glioma Therapy

Phase: Recruiting

First Posted: August

Condition(s): High Grade Glioma (HGG), Diffuse Intrinsic Pontine Glioma (DIPG), Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma

NCT Number: NCT05839379 Other Study ID Number(s): CONNECT TarGeT-SCR

What Is the Purpose of This Study?

The study aims to analyze the genes in brain tumors from kids, teens, and young adults who have just been diagnosed with a severe type of brain cancer. The results will help determine if they can join a follow-up treatment trial based on the genetic changes found in their tumors.

Who Can Take Part in This Study?

People who may be eligible for this study:

  • Are newly diagnosed with HGG, including DIPG.
  • Are aged ≥12 months and ≤30 years of age.

For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT05839379

What Will Happen During This Study?

  • Utilize molecular, clinical, and histopathologic data to assess eligibility for specific biologically guided treatment subprotocols among pediatric, adolescent and young adult patients with newly diagnosed HGG, including DIPG.
  • Determine the percent of pediatric, adolescent, and young adult patients newly diagnosed with HGG, including DIPG, who undergo comprehensive molecular characterization across clinical molecular testing laboratories at CONNECT sites and begin treatment on a TarGeT treatment subprotocol within 10 calendar days of starting radiation therapy (RT) (if treatment involves an agent given concurrently with RT) or within 35 days of completion of RT (if treatment involves adjuvant maintenance therapy).

Principal Investigator

Margot A. Lazow
MD

Hematology & Oncology

Principal Investigator

Maryam Fouladi
MD

Hematology & Oncology

Discover More Research
Explore additional studies relating to neuro-oncology